Function of the c-Myc oncogenic transcription factor

被引:318
|
作者
Dang, CV [1 ]
Resar, LMS
Emison, E
Kim, S
Li, Q
Prescott, JE
Wonsey, D
Zeller, K
机构
[1] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA
[2] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA
基金
美国国家卫生研究院;
关键词
oncogene; transcription factor; c-Myc; cell cycle; metabolism; cell adhesion; apoptosis; immortalization;
D O I
10.1006/excr.1999.4686
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The c-myc gene and the expression of the c-Myc protein are frequently altered in human cancers. The c-myc gene encodes the transcription factor c-Myc, which heterodimerizes with a partner protein, termed Max, to regulate gene expression. Max also heterodimerizes with the Mad family of proteins to repress transcription, antagonize c-Myc, and promote cellular differentiation The constitutive activation of c-myc expression is key to the genesis of many cancers, and hence the understanding of c-Myc function depends on our understanding of its target genes. In this review, we attempt to place the putative target genes of c-Myc in the context of c-Myc-mediated phenotypes. From this perspective, c-Myc emerges as an oncogenic transcription factor that integrates the cell cycle machinery with cell adhesion, cellular metabolism, and the apoptotic pathways. (C) 1999 Academic Press.
引用
收藏
页码:63 / 77
页数:15
相关论文
共 50 条
  • [31] Leishmania regulates host macrophage miRNAs expression by engaging transcription factor c-Myc
    Nandan, Devki
    Rath, Carolina Torturella
    Reiner, Neil E.
    JOURNAL OF LEUKOCYTE BIOLOGY, 2021, 109 (05) : 999 - 1007
  • [32] Arrest of hepatic oncogenesis and growth factor expansion by the c-Myc antagonist Mad transcription factor.
    Gagandeep, S
    Ott, M
    Nisen, P
    DePinho, R
    Gupta, S
    HEPATOLOGY, 1996, 24 (04) : 271 - 271
  • [33] Effects of an activation controlled by c-MYC transcription on the function and survival of pancreatic cells in mice
    Pascal, S. M. A.
    Pelengaris, S.
    Khan, M.
    Jonas, J. C.
    DIABETES & METABOLISM, 2008, 34 : A31 - A32
  • [34] A REPRESSOR OF C-MYC TRANSCRIPTION IS FOUND SPECIFICALLY IN PLASMACYTOMAS
    KAKKIS, E
    RIGGS, K
    CALAME, K
    CURRENT TOPICS IN MICROBIOLOGY AND IMMUNOLOGY, 1988, 141 : 231 - 237
  • [35] MODULATION OF C-MYC TRANSCRIPTION BY TRIPLE HELIX FORMATION
    POSTEL, EH
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES-SERIES, 1992, 660 : 57 - 63
  • [36] The non-enzymatic RAS effector RASSF7 inhibits oncogenic c-Myc function
    Kumaraswamy, Anbarasu
    Mamidi, Anitha
    Desai, Pavitra
    Sivagnanam, Ananthi
    Perumalsamy, Lakshmi Revathi
    Ramakrishnan, Chandrasekaran
    Gromiha, Michael
    Rajalingam, Krishnaraj
    Mahalingam, Sundarasamy
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2018, 293 (40) : 15691 - 15705
  • [37] NIPA CHECKPOINT CONTROL IS ESSENTIAL FOR EFFICIENT ONCOGENIC TRANSFORMATION BY C-MYC
    Illert, A. L.
    Fritz, C.
    Kawaguchi, H.
    Morris, S. W.
    Peschel, C.
    Keller, U.
    Duyster, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 206 - 206
  • [38] Phosphorylation Regulates c-Myc's Oncogenic Activity in the Mammary Gland
    Wang, Xiaoyan
    Cunningham, Melissa
    Zhang, Xiaoli
    Tokarz, Sara
    Laraway, Bryan
    Troxell, Megan
    Sears, Rosalie C.
    CANCER RESEARCH, 2011, 71 (03) : 925 - 936
  • [39] A strategy for combating melanoma with oncogenic c-Myc inhibitors and targeted nanotherapy
    Pan, Dipanjan
    Kim, Benjamin
    Hu, Grace
    Gupta, Deepti Sood
    Senpan, Angana
    Yang, Xiaoxia
    Schmieder, Anne
    Swain, Corban
    Wickline, Samuel A.
    Tomasson, Michael H.
    Lanza, Gregory M.
    NANOMEDICINE, 2015, 10 (02) : 241 - 251
  • [40] Inhibition of 5-lipoxygenase interrupts c-Myc oncogenic signaling
    Sarveswaran, Sivalokanathan
    Jin, Ren Jie
    Matusik, Robert J.
    Ghosh, Jagadananda
    CANCER RESEARCH, 2012, 72